ABSTRACT
A simple, ion-pair high-performance liquid chromatographic method has been developed and validated for the quantitative determination of the HIV protease inhibitor ritonavir in human plasma, cerebrospinal fluid and saliva. Sample pretreatment consisted of precipitation of proteins with acetonitrile prior to high-performance liquid chromatography with ultraviolet detection at 239 nm. The method has been validated over the range of 50 ng/ml to 50 microg/ml with use of 100-microl volumes of sample. The currently described assay has been used successfully for the analysis of ritonavir in plasma, cerebrospinal fluid and saliva in HIV-1 infected patients.
Subject(s)
HIV Protease Inhibitors/analysis , Ritonavir/analysis , Saliva/chemistry , Acquired Immunodeficiency Syndrome/blood , Acquired Immunodeficiency Syndrome/cerebrospinal fluid , Acquired Immunodeficiency Syndrome/metabolism , Chromatography, High Pressure Liquid , HIV Protease Inhibitors/blood , HIV Protease Inhibitors/cerebrospinal fluid , HIV Protease Inhibitors/pharmacokinetics , HIV-1 , Humans , Reproducibility of Results , Ritonavir/blood , Ritonavir/cerebrospinal fluid , Ritonavir/pharmacokinetics , Sensitivity and SpecificityABSTRACT
A high-performance liquid chromatographic method for the determination of the HIV protease inhibitor saquinavir in human plasma, saliva, and cerebrospinal fluid is described. Saquinavir was extracted from samples using C2 extraction columns prior to ion-pair, reversed-phase high-performance liquid chromatography with ultraviolet detection at 239 nm. The method has been validated over the range of 2.5-4000 ng/ml using a 0.6-ml sample volume. This assay has been used for the analysis of saquinavir in plasma and saliva of HIV-1-infected patients.
